CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-13 | DAWES KAREN A Director | Exercise or conversion | +2,929 | $41.19 | $121K | 118,982 |
| 2021-07-13 | DAWES KAREN A Director | Sale | −441 | $201.27 | $89K | 118,541 |
| 2021-07-13 | DAWES KAREN A Director | Sale | −630 | $202.29 | $127K | 117,911 |
| 2021-07-13 | DAWES KAREN A Director | Sale | −444 | $203.09 | $90K | 117,467 |
| 2021-07-13 | DAWES KAREN A Director | Sale | −5 | $204.02 | $1K | 117,462 |
| 2021-07-13 | DAWES KAREN A Director | Exercise or conversion · Stock Option (Right to Buy) | +2,929 | 0 | ||
| 2021-07-13 | DAWES KAREN A Director | Exercise or conversion | +2,929 | $41.19 | $121K | 118,982 |
| 2021-07-13 | DAWES KAREN A Director | Sale | +1,520 | $202.23 | $307K | 117,462 |
| 2021-07-13 | DAWES KAREN A Director | Exercise or conversion · Stock Option (Right to Buy) | +2,929 | 0 | ||
| 2021-06-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +2,557 | $59.52 | $152K | 27,112 |
| 2021-06-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +1,045 | $86.10 | $90K | 28,157 |
| 2021-06-10 | KURIYEL RALF Senior VP, R&D | Sale | −6,802 | $189.19 | $1.3M | 21,355 |
| 2021-06-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −2,557 | 1,354 | ||
| 2021-06-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −1,045 | 2,092 | ||
| 2021-05-19 | Hunt Anthony Chief Executive Officer | Sale | −612 | $168.29 | $103K | 212,150 |
| 2021-05-19 | Hunt Anthony Chief Executive Officer | Sale | −2,529 | $169.45 | $429K | 209,621 |
| 2021-05-19 | Hunt Anthony Chief Executive Officer | Sale | −7,911 | $170.28 | $1.3M | 201,710 |
| 2021-05-19 | Hunt Anthony Chief Executive Officer | Sale | −3,420 | $171.32 | $586K | 198,290 |
| 2021-05-19 | Hunt Anthony Chief Executive Officer | Sale | −3,036 | $172.52 | $524K | 195,254 |
| 2021-05-19 | Hunt Anthony Chief Executive Officer | Sale | −1,560 | $173.19 | $270K | 193,694 |
Page 27 of 42 · 832 trades